Dermal tophus: a complication of gout in a kidney transplant recipient.

Abstract

Gout is a chronic metabolic disease caused by disturbance of purine metabolism that leads to hyperuricemia. Hyperuricemia prevalence after renal transplant is reported as 19% to 84% in different studies. Tophaceous gout in renal transplant recipients is a consequence of increased hyperuricemia. Although tophus formation in skin and soft tissues is an indicator of chronic gout (also referred to as tophaceous gout), tophi may be the first sign of gout. In this study, we report a case of a 62-year-old male renal transplant recipient who had tophi as the first clinical sign of gout. After confirming gout diagnosis, cyclosporine was changed to sirolimus, and allopurinol was added to therapy to decrease uric acid levels. In conclusion, hyperuricemia is a common complication in renal transplant recipients. Presentation might be atypical, and diagnosis can be challenging.

• Authors: Ebru Hatice Ayvazoglu Soy, Emre Karakaya, Arzu Karatas Togral, Aydincan Akdur, Gokhan Moray, Mehmet Haberal
• Journal: Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation (Exp Clin Transplant) Vol. 13 Suppl 1 Pg. 276-9 (Apr 2015) ISSN: 2146-8427 [Electronic] Turkey
• PMID: 25894172 (Publication Type: Case Reports, Journal Article)

Chemical References

• Gout Suppressants
• Immunosuppressive Agents
• Allopurinol
• Cyclosporine
• Sirolimus

Topics

• Allopurinol (therapeutic use)
• Cyclosporine (therapeutic use)
• Drug Substitution
• Gout (diagnosis, drug therapy, etiology)
• Gout Suppressants (therapeutic use)
• Humans
• Hyperuricemia (diagnosis, drug therapy, etiology)
• Immunosuppressive Agents (therapeutic use)
• Kidney Transplantation (adverse effects)
• Male
• Middle Aged
• Risk Factors
• Sirolimus (therapeutic use)
• Skin (drug effects, pathology)
• Treatment Outcome